三阴性乳腺癌
乳腺癌
化学
表皮生长因子受体
癌症研究
靶向治疗
转移
癌症
脂质体
体内
内科学
医学
生物
生物技术
生物化学
作者
Haiyan Gu,Rui Shi,Xu Chen,Wenhao Lv,Xueyin Hu,Canxin Xu,Yuanbo Pan,Xiahong He,Aiguo Wu,Juan Li
标识
DOI:10.1021/acs.bioconjchem.3c00207
摘要
Triple-negative breast cancer (TNBC) remains the most challenging breast cancer subtype due to its lack of targeted therapies and poor prognosis. In order to treat patients with these tumors, efforts have been made to explore feasible targets. Epidermal growth factor receptor (EGFR)-targeted therapy is currently in clinical trials and regarded to be a promising treatment strategy. In this study, an EGFR-targeting nanoliposome (LTL@Rh2@Lipo-GE11) using ginsenoside Rh2 as a wall material was developed, in which GE11 was used as the EGFR-binding peptide to deliver more ginsenoside Rh2 and luteolin into TNBC. In comparison to non-targeted liposomes (Rh2@Lipo and LTL@Rh2@Lipo), the nanoliposomes LTL@Rh2@Lipo-GE11 demonstrated a high specificity to MDA-MB-231 cells that expressed a high level of EGFR both in vitro and in vivo, contributing to the strong inhibitory effects on the growth and migration of TNBC. These results suggest that LTL@Rh2@Lipo-GE11 is a prospective candidate for targeted therapy of TNBC, with a remarkable capability to inhibit tumor development and metastasis.
科研通智能强力驱动
Strongly Powered by AbleSci AI